A new ICT-based device (RHEO-01) for fast point-of-care analysis of acute ischemic stroke and other emergency situations.

Información del proyecto

ERYTHROAG

Identificador del acuerdo de subvención: 735480

DOI

10.3030/735480

Proyecto cerrado

Fecha de la firma de la CE 24 Julio 2016

Fecha de inicio 1 Agosto 2016

Fecha de finalización 31 Enero 2017

Financiado con arreglo a

• SOCIETAL CHALLENGES - Health, demographic change and well-being

Coste total

€ 71 429,00

Aportación de la UE

€ 50 000,00

Coordinado por

RHEOFAST
France

Objetivo

Stroke is the most frequent cause of long-term disability in Europe, mainly in middle-aged and elderly people. Stroke imposes a huge health care economic burden: >5B€/year in France. RHEOFAST is developing a smart ICT-based decision support tool to assist health professionals in the efficient management of patients with acute stroke. RHEO-01 information management includes three aspects:
1- High quality data input from a connected point-of-care device that measure a patient’s inflammatory profile in 30s. The optically measured erythrocyte aggregation kinetics (EA) varies with inflammation. This information is contextualized by the patient’s clinical characteristics provided by physicians.
2-Remote smart data is managed with EA kinetics mathematical modelling, comparison with proprietary dataset and dataset enrichment with high quality data,
3- Physician-friendly output is displayed on the POC device to help physicians make treatment decisions. The whole process from standard blood collection to results takes less than 5 minutes.
Acute ischemic stroke triggers inflammation, which in turn alters EA kinetics. Hemorrhagic stroke doesn’t initially trigger inflammation. By helping physicians to quickly differentiate patients with acute ischemic stroke from patients with hemorrhagic stroke, RHEO-01 will improve the percentage of patients receiving timely life-saving thrombolytic therapy. A 1% increase in thrombolytic treatment translates to a 440K€ decrease in cost (France). Furthermore, RHEO-01 can quickly identify inflammatory profiles in patients with other emergency conditions. Based on the French situation RHEOFAST forecasts a rapid growing turnover starting in 2018 with up to 13 M€ after 5 years. We need to have a European approach to update our forecast and propose our solution to health professionals all across Europe. This is the objective of the ERYTHROAG project, which includes technical risk analysis, market research and freedom to operate study.

Ámbito científico (EuroSciVoc)

• ciencias médicas y de la salud › medicina clínica › cardiología › enfermedad cardiovascular
• ciencias médicas y de la salud › medicina básica › neurología › accidente cerebrovascular
• ciencias naturales › informática y ciencias de la información › ciencia de datos › tratamiento de datos
• ciencias naturales › matemáticas › matemáticas aplicadas › modelo matemático

Programa(s)

• H2020-EU.3.1. - SOCIETAL CHALLENGES - Health, demographic change and well-being PROGRAMA PRINCIPAL
  
• H2020-EU.3.1.4. - Active ageing and self-management of health
  
• H2020-EU.2.1.1. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies - Information and Communication Technologies (ICT)
  
• H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
  
• H2020-EU.3.1.6. - Health care provision and integrated care
  

Tema(s)

• SMEInst-06-2016-2017 - Accelerating market introduction of ICT solutions for Health, Well-Being and Ageing Well
  

Régimen de financiación

SME-1 - SME instrument phase 1

Convocatoria de propuestas

H2020-SMEInst-2016-2017

Coordinador

RHEOFAST

• Aportación neta de la UEn: € 50 000,00
• Dirección: 5 RUE HENRI DESBRUERES, GENOPOLE CAMPUS 1 ; 91030 EVRY ; Francia
• Pyme Sí:
  Región
  Ile-de-France › Ile-de-France › Essonne
• Región: Ile-de-France › Ile-de-France › Essonne
• Tipo de actividad: Private for-profit entities (excluding Higher or Secondary Education Establishments)
• Coste total: € 71 429,00